Vol. 19/No. 12 | OncologyLive

FDA Strategizes to Step Up Introduction of Lower-Cost Drugs and NGS

June 19, 2018

The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines with a strategy that includes an attempt to reduce anticompetitive behavior.

Patients Aged

June 13, 2018

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.